IgAN374.xls

In this study, baseline
demographics , clinical and pathology data were collected for all patients
during renal biopsies, including age, gender, mean arterial pressure (MAP)
defined as diastolic pressure plus one-third of the pulse pressure, 24-hour
protein excretion and estimated glomerular filtration rate (eGFR) calculated by
the Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration equation.
Regardless of the duration and dose, the type of immunosuppression or renin-angiotensin-aldosterone system (RAAS) blockades
therapy that the patient received was recorded. Immunosuppression
was defined as treatment with corticosteroids and/or corticosteroid-sparing
agents (including cyclophosphamide, azathioprine, mycophenolate, cyclosporine
or tacrolimus). RAAS blockades included any exposure to angiotensin-converting
enzyme inhibitor and/or angiotensin receptor blocker after biopsy. The
updated Oxford Classification(MEST-C) for IgAN was applied in this study[5]. Renal biopsy samples from all patients were examined
by pathologist and nephrologist. The crescent is subdivided according to the
volume, composition and proportion of the crescent. The volume of the crescent
body is defined as the large crescent body accounting for 50% or more of the
renal sac volume and the small crescent body accounting for 50% or less of the
renal sac volume. The components of crescent body can be divided into cellular
crescent, cellular fibrous crescent and fibrous crescent. The cellular crescent
consists of > 75% cells and < 25% fibrous matrix. The fibrous
cellular crescent consists of 25%-75% of the cells and the remaining
fibrous matrix. Extracapillary fibrosis of fibrous crescents consists of >
75% matrix and < 25% cells. The crescent ratio is defined as the proportion
of the number of glomeruli with crescents in the total number of glomeruli, and
the cell / fibrous cell / fibrous crescent is evaluated according to the
relative ratio. ESRD was defined as eGFR<15 mL/min/1.73 m2 for more than 3
months or initiation of dialysis or transplantation. In this study, we defined clinical outcome: the combined event (Doubling of
serum creatinine, 50% reduction in eGFR, 15% reduction in eGFR within 1 year,
30% reduction in eGFR within 2 year,
ESRD or death ) after diagnostic kidney biopsy.